Smarter cannabinoid monitoring could improve pain treatment
Biosensing technologies for cannabinoid monitoring in pain management: Current methods, clinical needs, and translational challenges.
AI Summary
THC and CBD are being investigated for chronic and neuropathic pain, but their clinical use is complicated by variable products, uncertain therapeutic ranges, and limited evidence connecting blood or tissue concentrations with benefits and side effects. This review examines both established laboratory approaches—such as chromatography, mass spectrometry, and spectroscopy—and newer biosensors designed to detect cannabinoids in biological samples.
The review finds that portable electrochemical sensors and compact optical or immunoassay devices appear to be the most promising near-term options for point-of-care monitoring. However, most cannabinoid biosensors remain at a preliminary stage. Before they can support routine therapeutic drug monitoring, they need testing in real patient samples, comparison with trusted reference methods, better reproducibility and stability, and clearer links between cannabinoid concentrations, pain relief, and adverse effects. The abstract reports no quantitative clinical results.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Small lab study finds cannabis affected simulated driving and confidence
A lab method measures 17 cannabinoids across five hemp product types
A single-center study finds varied care and no recurrence in follow-up
Explore More Research
Stay informed about the latest cannabis science.